Literature DB >> 21327401

Serum uric acid levels in multiple sclerosis patients inversely correlate with disability.

A L Guerrero1, F Gutiérrez, F Iglesias, J Martín-Polo, S Merino, J I Martín-Serradilla, E Laherrán, M A Tejero.   

Abstract

Uric acid (UA) is an endogenous antioxidant. Some studies have described that multiple sclerosis (MS) patients have lower serum UA levels than controls, although it has not been established whether UA is primarily deficient, or secondarily reduced due to its scavenging activity. UA has also been proposed as an indicator of disease activity. We, retrospectively, reviewed 478 serum UA levels obtained in 94 MS patients. Ninety samples were collected during a relapse. Correlation between UA levels obtained during a relapse or in a relapse-free period, and comparison between UA and expanded disability status scale (EDSS) score was tested using a two-tailed Student's t test and Spearman correlation coefficients test. UA levels were significantly lower when measured during a relapse (n 90) than in a remission period (n 368) (r -0.16, p 0.003) UA levels measured outside a relapse inversely correlated with EDSS score (r -0.15, p 0.001). Lower uric acid levels in MS patients are associated with clinical relapse. This is the first description of an inverse correlation of serum UA levels with disability as assessed by EDSS score.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21327401     DOI: 10.1007/s10072-011-0488-5

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  20 in total

1.  Serum uric acid levels and leukocyte nitric oxide production in multiple sclerosis patients outside relapses.

Authors:  Jop P Mostert; Geeta S M Ramsaransing; Dorothea J Heersema; Marco Heerings; Nadine Wilczak; Jacques De Keyser
Journal:  J Neurol Sci       Date:  2005-01-20       Impact factor: 3.181

2.  Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis.

Authors:  G S M Ramsaransing; D J Heersema; J De Keyser
Journal:  Eur J Neurol       Date:  2005-07       Impact factor: 6.089

3.  The role of uric acid in protection against peroxynitrite-mediated pathology.

Authors:  G S Scott; D C Hooper
Journal:  Med Hypotheses       Date:  2001-01       Impact factor: 1.538

4.  Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors.

Authors:  Gwen S Scott; Sergei V Spitsin; Rhonda B Kean; Tatiana Mikheeva; Hilary Koprowski; D Craig Hooper
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-25       Impact factor: 11.205

5.  Uric acid levels in sera from patients with multiple sclerosis.

Authors:  J Drulović; I Dujmović; N Stojsavljević; S Mesaros; S Andjelković; D Miljković; V Perić; G Dragutinović; J Marinković; Z Lević; M Mostarica Stojković
Journal:  J Neurol       Date:  2001-02       Impact factor: 4.849

6.  Serum uric acid and multiple sclerosis.

Authors:  S Sotgiu; M Pugliatti; A Sanna; A Sotgiu; M L Fois; G Arru; G Rosati
Journal:  Neurol Sci       Date:  2002-10       Impact factor: 3.307

7.  Serum uric acid levels of patients with multiple sclerosis and other neurological diseases.

Authors:  Fuhua Peng; Bin Zhang; Xiufeng Zhong; Jin Li; Guihong Xu; Xueqiang Hu; Wei Qiu; Zhong Pei
Journal:  Mult Scler       Date:  2007-10-17       Impact factor: 6.312

8.  Uric acid and renal function in multiple sclerosis.

Authors:  E L Kanabrocki; M D Ryan; R C Hermida; D E Ayala; J B McCormick; S Dawson; L Lojo; H S Hoffman; G Siegel; N Friedman; B Eladasori; R Parachuri; B A Nemchausky
Journal:  Clin Ter       Date:  2008 Jan-Feb

9.  Serum uric acid and risk of multiple sclerosis.

Authors:  Jennifer Massa; E O'Reilly; K L Munger; G N Delorenze; A Ascherio
Journal:  J Neurol       Date:  2009-05-26       Impact factor: 4.849

10.  Blood lipids, homocysteine, stress factors, and vitamins in clinically stable multiple sclerosis patients.

Authors:  Giuseppe Salemi; Maria Concetta Gueli; Francesco Vitale; Floriana Battaglieri; Egidio Guglielmini; Paolo Ragonese; Angela Trentacosti; Maria Fatima Massenti; Giovanni Savettieri; Antonino Bono
Journal:  Lipids Health Dis       Date:  2010-02-18       Impact factor: 3.876

View more
  9 in total

1.  Urinary Urea, Uric Acid and Hippuric Acid as Potential Biomarkers in Multiple Sclerosis Patients.

Authors:  Hanaa B Atya; Sahar A Ali; Mohamed I Hegazy; Fathia Z El Sharkawi
Journal:  Indian J Clin Biochem       Date:  2017-05-22

2.  Serum uric acid concentrations are directly associated with the presence of benign multiple sclerosis.

Authors:  Esteban Simental-Mendía; Luis E Simental-Mendía; Fernando Guerrero-Romero
Journal:  Neurol Sci       Date:  2017-06-28       Impact factor: 3.307

3.  Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis.

Authors:  Giacomo Lazzarino; Angela M Amorini; Axel Petzold; Claudio Gasperini; Serena Ruggieri; Maria Esmeralda Quartuccio; Giuseppe Lazzarino; Enrico Di Stasio; Barbara Tavazzi
Journal:  Mol Neurobiol       Date:  2016-11-08       Impact factor: 5.590

4.  Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study.

Authors:  Marcello Moccia; Roberta Lanzillo; Teresa Costabile; Cinzia Russo; Antonio Carotenuto; Gabriella Sasso; Emanuela Postiglione; Carla De Luca Picione; Michele Vastola; Giorgia Teresa Maniscalco; Raffaele Palladino; Vincenzo Brescia Morra
Journal:  J Neurol       Date:  2015-02-12       Impact factor: 4.849

5.  Lower serum uric acid levels in cerebral amyloid angiopathy: a pilot study.

Authors:  Qi Hu; Anding Liu; Mengyang Huang; Luo Cheng; Huicong Kang; Feng Xu; Xiaoyan Liu; Lifei Lian; Qiming Liang; Hong Jiang; Cuntai Zhang; Suiqiang Zhu
Journal:  Neurol Sci       Date:  2014-01-25       Impact factor: 3.307

6.  Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelination attacks.

Authors:  Srdjan Ljubisavljevic; Ivana Stojanovic; Slobodan Vojinovic; Maja Milojkovic; Olivera Dunjic; Dragan Stojanov; Dusica Pavlovic
Journal:  Metab Brain Dis       Date:  2013-04-23       Impact factor: 3.584

7.  Oral administration of inosine promotes recovery after experimental spinal cord injury in rat.

Authors:  Maria Kuricova; Valent Ledecky; Tomas Liptak; Aladar Madari; Ivana Grulova; Lucia Slovinska; Miriam Nagyova; Dasa Cizkova
Journal:  Neurol Sci       Date:  2014-06-10       Impact factor: 3.307

Review 8.  Asymptomatic hyperuricemia: is it time to intervene?

Authors:  Binoy J Paul; K Anoopkumar; Vinod Krishnan
Journal:  Clin Rheumatol       Date:  2017-10-04       Impact factor: 2.980

9.  Predicting disease activity in patients with multiple sclerosis: An explainable machine-learning approach in the Mavenclad trials.

Authors:  Sreetama Basu; Alain Munafo; Ali-Frederic Ben-Amor; Sanjeev Roy; Pascal Girard; Nadia Terranova
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-05-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.